Clinical Trial Search

Primary: Effect of Ibuprofen, Diphenhydramine and Aluminium MgS Measured on Decrease in Pain Level and Burning Sensation — 3.176; 3.821 scores in Visual Analogue Scale

Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale

Primary: Oral Intake in ml/kg — 9.7; 10.7 oral intake in ml/kg

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05

Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Lesion Healing — 107.47; 110.08; 112.41 hours

Primary: Percentage of Subjects With at Least 2 mm Keratinized Tissue (KT) at 6 Months at the Gintuit Treated Site. — 95.3 percentage of participants — p=<0.0001

Primary: Number of Participants With Stomatitis Grade ≥ 2 — 2; 83; 1 Participants — p=<0.001

Primary: Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose — 128; 163; 174 days

Primary: The Change of Abundance of Specific Oral Microbes After Intervention as Assessed by 16S rRNA Sequencing — 0.00756; 0.14636; 0.00629; 0.11956 percentage of bacteria

Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57

Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…

Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061

Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale

Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30

Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404

Primary: Incidence of Oral Mucositis — 66; 10; 64 percentage of participants

Primary: Duration of Severe Oral Mucositis (WHO Grade 3 or 4) — 4.5; 4.5 Number of days

Primary: Change From Baseline in Oral Aperture Measurement — 32.98; 32.92; 33.40; 34.37 milimeters — p=0.564

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index — 0.41; 0.43 score on a scale

Primary: Duration of Severe Oral Mucositis (SOM) — 22.9; 27.7; 35.2; 37.8 Days

Primary: Gingival Index — 1.90; 1.84 Units on a scale — p=0.005

Primary: Change in Absent in Melanoma 2 (AIM2) mRNA Expression Levels — 0.37; 0.65 fold change — p=0.3

Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants